Mirabegron Stada

Mirabegron, the active ingredient in Mirabegron Stada, is a β3‑adrenergic receptor agonist presented as an oral tablet for oral use. It relaxes detrusor smooth muscle to increase bladder capacity and is used to manage overactive bladder symptoms in adults.

GNH USA supplies Mirabegron Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirabegron is indicated for conditions affecting bladder storage function within the overactive bladder disease family.

- Overactive bladder: improves urgency, frequency and urge incontinence. - Urinary urgency: reduces the sudden need to void. - Urinary frequency: decreases the number of daytime voids.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Dry mouth: mild to moderate reduction in salivation. - Hypertension: increase in blood pressure. - Nasopharyngitis: upper respiratory tract infection symptoms. - Headache: mild to moderate headache. - Constipation: reduced bowel movements. - Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects: - Urinary retention: difficulty emptying the bladder. - Severe hypertension: markedly elevated blood pressure requiring medical attention. - Tachyarrhythmia: abnormal rapid heart rhythm. - Angioedema: swelling of face, lips or throat. - Acute renal failure: sudden loss of kidney function.

Patients should be evaluated for cardiovascular and renal status before initiating therapy.

- Blood pressure monitoring: check baseline and periodic readings. - Renal function assessment: evaluate creatinine clearance before use. - Cardiovascular disease: use cautiously in patients with known heart disease. - Drug interactions: review concomitant medications for potential additive effects. - Pregnancy and lactation: safety not established; avoid unless benefit outweighs risk. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Mirabegron may alter the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - CYP2D6 substrates (e.g., metoprolol): may increase plasma levels. - Antihypertensives (e.g., ACE inhibitors): may reduce blood pressure control.

Moderate Interactions (Monitor Closely): - Anticholinergics: additive effect on urinary retention. - Diuretics: potential for altered fluid balance. - NSAIDs: increased risk of hypertension. - Digoxin: possible increase in serum concentration. - Warfarin: monitor INR for potential changes.